Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Vandana Singh

Cyclacel To Test Higher Doses Of Fadraciclib In Solid Tumor Patients

  • Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) is adding two dose levels in a protocol amendment to test higher doses of oral fadraciclib before determining the recommended Phase 2 dose anticipated in 2H of 2022, citing the absence of dose-limiting toxicities.
  • Fifteen patients with advanced solid tumors and lymphomas were treated with oral fadraciclib at all five doses.
  • In the first oral treatment cycle with fadraciclib, a cutaneous T cell lymphoma patient achieved partial response (PR).
  • A patient with a peripheral T cell lymphoma achieved a 38% reduction in target lesions.
  • An endometrial cancer patient achieved stable disease with a 15% reduction of target lesions after the first oral treatment cycle. In an earlier study of intravenous fadraciclib as monotherapy, a patient with MCL1 amplified endometrial cancer achieved confirmed complete response (CR) and remains on study after 2.5 years of treatment.
  • A pancreatic cancer patient achieved stable disease by the confirmatory scan for five oral treatment cycles.
  • For CYC140, no dose-limiting toxicities were observed to date in the Phase 1/2 study of oral CYC140.
  • An ovarian cancer patient in 140-101 achieved stable disease with tumor shrinkage after the first cycle.
  • Price Action: CYCC shares are down 28.4% at $1.06 during the market session on the last check Thursday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.